-transparent.png){kind=logo}
Thirty-seven patients with advanced malignancies, who received cis-platinum-based combination chemotherapy, were evaluated for the antiemetic efficacy of high-dose metoclopramide. Most of the patients suffered from ovarian carcinoma. The dose of metoclopramide was 7.5 or 10 mg/kg per course. A total of 69 courses were given to 37 patients and in 22% of the courses, nausea and vomiting were eliminated altogether. In an additional 48% of the courses, a partial protection from chemotherapy-induced emesis was evident. No serious side effects were observed. The administration of high-dose metoclopramide is recommended for prevention of cis-platinum chemotherapy-induced emesis.
E Gez, and
R Catane, and
L Pfau, and
S Biran
January 1982,
Oncology nursing forum,
E Gez, and
R Catane, and
L Pfau, and
S Biran
January 1987,
Oncology,
E Gez, and
R Catane, and
L Pfau, and
S Biran
June 1989,
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,
E Gez, and
R Catane, and
L Pfau, and
S Biran
January 1986,
Oncology,
E Gez, and
R Catane, and
L Pfau, and
S Biran
July 1982,
The New England journal of medicine,
E Gez, and
R Catane, and
L Pfau, and
S Biran
January 1992,
Oncology,
E Gez, and
R Catane, and
L Pfau, and
S Biran
September 1986,
Japanese journal of clinical oncology,
E Gez, and
R Catane, and
L Pfau, and
S Biran
March 1986,
European journal of cancer & clinical oncology,
E Gez, and
R Catane, and
L Pfau, and
S Biran
September 1984,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
E Gez, and
R Catane, and
L Pfau, and
S Biran
January 1991,
Oncology,
